IV Magnesium in the Treatment of Acute Dysmenorrhea

Havva Betül Bacak60 enrolled

Overview

This prospective, randomized, double-blind clinical trial aims to evaluate the analgesic efficacy of intravenous magnesium sulfate in women presenting to the emergency department with acute dysmenorrhea. Participants will be randomized into two groups receiving either 2 ampoules of magnesium sulfate or intravenous dexketoprofen. Pain levels will be assessed using the Visual Analog Scale (VAS) before and after treatment.

This prospective, randomized, double-blind clinical trial is designed to evaluate the analgesic effectiveness of intravenous magnesium sulfate in women aged 18 to 35 years presenting to the emergency department with acute dysmenorrhea. Participants will be randomly assigned to one of two treatment groups: 2 ampoules of magnesium sulfate or intravenous dexketoprofen. All medications will be diluted in 100 ml of normal saline and administered intravenously over 15 minutes. Pain intensity will be assessed using the Visual Analog Scale (VAS) before treatment and 1 hour after administration. Secondary outcomes include patient satisfaction, vital sign changes, and adverse effects. The study aims to compare the analgesic efficacy and safety profile of intravenous magnesium sulfate with that of a standard nonsteroidal anti-inflammatory drug (dexketoprofen) in the management of acute dysmenorrhea.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dysmenorrhea

Interventions

Magnesium Sulfate (2 Ampoules)DRUG

Intravenous administration of 2 ampoules (8 ml total) of magnesium sulfate diluted in 100 ml normal saline, infused over 15 minutes.

DexketoprofenDRUG

Intravenous administration of 50 mg dexketoprofen diluted in 100 ml normal saline, infused over 15 minutes.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: Female patients aged 18 to 35 years Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea Having regular menstrual cycles within the last 6 months Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission Providing written informed consent for participation in the study Exclusion Criteria: Patients with secondary dysmenorrhea or underlying gynecological pathology Pregnancy or breastfeeding Use of analgesics or muscle relaxants within the last 3 days Known allergy to magnesium sulfate or dexketoprofen trometamol History of renal failure, cardiac arrhythmia, or serious systemic disease Inability to assess pain due to mental disability or communication disorder Failure to provide informed consent for participation in the study

Locations (1)

SBÜ Gaziosmanpaşa Training and Research Hospital

Gaziosmanpaşa, Outside of the US, Turkey (Türkiye)

RECRUITING

Outcomes

Primary Outcomes

Change in pain intensity measured by Visual Analog Scale (VAS)

Pain severity will be assessed using the 0-10 Visual Analog Scale (VAS) before treatment and 1 hour post-treatment. The study will evaluate and compare the analgesic effect of two different doses of intravenous magnesium sulfate (2 ampoules vs. 3 ampoules) and compare both to intravenous dexketoprofen in women presenting with acute dysmenorrhea.

Time frame: Baseline and 1 hour after intravenous treatment

Central Contacts

ecenur çelikoğlu, md

CONTACT

+90 538 54 92 848 ecenurcelikoglu14@gmail.com

yağmur acıyiyen, md

CONTACT

+905425669593 yagmuraciyiyen95@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.